Literature DB >> 21669029

Programmatic management of multidrug-resistant tuberculosis: models from three countries.

J Furin1, J Bayona, M Becerra, P Farmer, A Golubkov, R Hurtado, J K Joseph, S Keshavjee, O Ponomarenko, M Rich, S Shin.   

Abstract

BACKGROUND: Although multidrug-resistant tuberculosis (MDR-TB) is a major global health problem, there is a gap in programmatic treatment implementation.
METHODS: This study describes MDR-TB treatment models in three countries--Peru, Russia and Lesotho-- using qualitative data collected over a 13-year period.
RESULTS: A program analysis is presented for each country focusing on baseline medical care, initial implementation and program evolution. A pattern analysis revealed six overarching themes common to all three programs: 1) importance of baseline assessments, 2) early identification of key collaborators, 3) identification of initial locus of care, 4) minimization of patient-incurred costs, 5) targeted interventions for vulnerable populations and 6) importance of technical assistance and funding. Site commonalities and differences in each of these areas were analyzed.
CONCLUSIONS: It is recommended that all programs providing MDR-TB treatment address these six areas during program development and implementation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21669029     DOI: 10.5588/ijtld.10.0591

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  9 in total

1.  On the spread and control of MDR-TB epidemics: an examination of trends in anti-tuberculosis drug resistance surveillance data.

Authors:  Ted Cohen; Helen E Jenkins; Chunling Lu; Megan McLaughlin; Katherine Floyd; Matteo Zignol
Journal:  Drug Resist Updat       Date:  2014-10-06       Impact factor: 18.500

2.  GeneXpert--a game-changer for tuberculosis control?

Authors:  Carlton A Evans
Journal:  PLoS Med       Date:  2011-07-26       Impact factor: 11.069

3.  Health system support and health system strengthening: two key facilitators to the implementation of ambulatory tuberculosis treatment in Uzbekistan.

Authors:  Stefan Kohler; Damin Abdurakhimovich Asadov; Andreas Bründer; Sean Healy; Atadjan Karimovich Khamraev; Natalia Sergeeva; Peter Tinnemann
Journal:  Health Econ Rev       Date:  2016-07-12

4.  The experience of scaling up a decentralized, ambulatory model of care for management of multidrug-resistant tuberculosis in two regions of Ethiopia.

Authors:  Yohannes Molla; Degu Jerene; Ilili Jemal; Gebrie Nigussie; Tenagne Kebede; Yewulsew Kassie; Nebiyu Hiruy; Getachew Aschale; Dereje Habte; Zewdu Gashu; Yared Kebede Haile; Muluken Melese; Pedro Suarez
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2017-03-06

5.  Can Brazil play a more important role in global tuberculosis drug production? An assessment of current capacity and challenges.

Authors:  Andre Gemal; Joel Keravec; Alexandre Menezes; Anete Trajman
Journal:  BMC Public Health       Date:  2013-03-27       Impact factor: 3.295

6.  Factors associated with the rapid implementation process of the fixed-dose combination RHZE tuberculosis regimen in Brazil: an ecological study.

Authors:  José Ueleres Braga; Deborah Araújo da Conceição; Anete Trajman
Journal:  BMC Public Health       Date:  2013-04-09       Impact factor: 3.295

7.  Effectiveness of a government-organized and hospital-initiated treatment for multidrug-resistant tuberculosis patients--a retrospective cohort study.

Authors:  Pei-Chun Chan; Su-Hua Huang; Ming-Chih Yu; Shih-Wei Lee; Yi-Wen Huang; Shun-Tien Chien; Jen-Jyh Lee
Journal:  PLoS One       Date:  2013-02-25       Impact factor: 3.240

8.  "Home is where the patient is": a qualitative analysis of a patient-centred model of care for multi-drug resistant tuberculosis.

Authors:  Shona Horter; Beverley Stringer; Lucy Reynolds; Muhammad Shoaib; Samuel Kasozi; Esther C Casas; Meggy Verputten; Philipp du Cros
Journal:  BMC Health Serv Res       Date:  2014-02-21       Impact factor: 2.655

9.  The production and sales of anti-tuberculosis drugs in China.

Authors:  Yang-Mu Huang; Qi-Peng Zhao; Qiao-Meng Ren; Dan-Lu Peng; Yan Guo
Journal:  Infect Dis Poverty       Date:  2016-10-04       Impact factor: 4.520

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.